ARQULE INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-11-07: Form 8-K; Period of report 2013-11-07; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2013-09-30: Form 8-K; Period of report 2013-09-30; Description 8.01 Other Events; Details 8.01.
- 2013-09-03: Form 8-K; Period of report 2013-09-03; Description 8.01 Other Events; Details 8.01.
- 2013-07-30: Form 8-K; Period of report 2013-07-24; Description 2.02 Results of Operations and Financial Condition; 2.05 Costs Associated with Exit or Disposal Activities; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-11-07 | 8-K | 2013-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2013 ArQule, Inc. (the “Registrant”) issued a press release announcing its results of operations for the fiscal quarter ended September 30, 2013. | t77746_8k.htm |
| 2013-09-30 | 8-K | 2013-09-30 | 8.01 Other Events | 8.01 On September 30, 2013, ArQule, Inc. (the “Registrant”) reported that data presented at the European Cancer Congress demonstrated clinical benefits of treatment with the combination of tivantinib and erlotinib in patients with non-squamous, non-small cell lung cancer whose tumors expressed high levels of met protein. | t77471_8k.htm |
| 2013-09-03 | 8-K | 2013-09-03 | 8.01 Other Events | 8.01 ArQule, Inc. (“ArQule” or the “Company”) and its partner, Daiichi Sankyo, Inc. (“Daiichi Sankyo”) are currently sponsoring a Phase 3 trial of tivantinib in the treatment of hepatocellular cancer (“HCC”). | t77325_8k.htm |
| 2013-07-30 | 8-K | 2013-07-24 | 2.02 Results of Operations and Financial Condition; 2.05 Costs Associated with Exit or Disposal Activities | 2.02 On July 30, 2013 ArQule, Inc. (the “Registrant” or the “Company”) issued a press release announcing (i) its results of operations for the fiscal quarter ended June 30, 2013 and (ii) a focused reduction in its workforce. 2.05 On July 24, 2013, the Company approved, effective as of July 29, 2013, a focused reduction in the Company’s workforce of approximately 25 positions resulting in a remaining workforce of approximately 67 employees. | t77043_8k.htm |
| 2013-06-03 | 8-K | 2013-06-01 | 7.01 Regulation FD Disclosure | 7.01 On June 1, 2013, ArQule, Inc. (the “Registrant”) announced final results from a randomized, placebo-controlled, double-blind, phase 2 clinical trial with the selective MET inhibitor tivantinib in combination with cetuximab and irinotecan as an investigational, second-line treatment in KRAS wild-type metastatic colorectal cancer (CRC). | t76695_8k.htm |
| 2013-05-23 | 8-K | 2013-05-20 | 5.07 Submission of Matters to a Vote of Security Holders | t76481_8k.htm | |
| 2013-05-08 | 8-K | 2013-05-08 | 2.02 Results of Operations and Financial Condition | 2.02 On May 8, 2013 ArQule, Inc. (the “Registrant”) issued a press release announcing its results of operations for the fiscal quarter ended March 31, 2013. | t76481_8k.htm |
| 2013-04-01 | 8-K | 2013-03-26 | 1.02 Termination of a Material Definitive Agreement | 1.02 As previously reported, on November 10, 2011, ArQule, Inc. (“ArQule” or the “Registrant”) announced that it entered into a license and co-commercialization agreement (the “License Agreement”) with Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”) to develop and commercialize ARQ 092, an inhibitor of the serine/threonine kinase, AKT, and certain backup compounds. | t76075_8k.htm |
| 2013-03-14 | 8-K | 2013-03-14 | 2.02 Results of Operations and Financial Condition | 2.02 On March 14, 2013, ArQule, Inc. (the “Registrant”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2012. | t75860_8k.htm |
| 2013-03-11 | 8-K | 2013-03-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | t75806_8k.htm | |
| 2013-01-31 | 8-K | 2013-01-31 | 8.01 Other Events | 8.01 On January 31, 2013, ArQule, Inc. (the “Registrant”) and Daiichi Sankyo Co., Ltd. (Daiichi Sankyo”) announced that the first patient has been enrolled in their pivotal Phase 3 METIV-HCC clinical trial of tivantinib (ARQ 197), an investigational selective inhibitor of MET, in patients diagnosed with hepatocellular carcinoma (HCC) who have received one or two prior systemic anti-cancer therapies. | t75497_8k.htm |
| 2013-01-11 | 8-K | 2013-01-11 | 8.01 Other Events | 8.01 On January 11, 2013, ArQule, Inc. (the “Registrant”) and Daiichi Sankyo, Co., Ltd. (Daiichi Sankyo”) announced the top-line results of a randomized Phase 2 signal generation trial of tivantinib used in combination with irinotecan and cetuximab in patients with refractory or relapsed colorectal cancer. | t75359_8k.htm |